Kalaris Therapeutics, Inc. financial data

Symbol
KLRS on Nasdaq
Location
Berkeley Heights, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 603% % -59%
Debt-to-equity 281% %
Return On Equity -290% % -258%
Return On Assets -64% % 12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18,702,418 shares -84%
Common Stock, Shares, Outstanding 18,702,418 shares -84%
Entity Public Float $58,800,000 USD -78%
Common Stock, Value, Issued $2,000 USD -82%
Weighted Average Number of Shares Outstanding, Basic 18,701,708 shares 1283%
Weighted Average Number of Shares Outstanding, Diluted 18,701,708 shares 1283%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,256,000 USD -114%
General and Administrative Expense $51,264,000 USD 270%
Operating Income (Loss) $56,193,000 USD 47%
Nonoperating Income (Expense) $847,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $45,068,000 USD 58%
Earnings Per Share, Basic 19 USD/shares 98%
Earnings Per Share, Diluted 19 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $42,387,000 USD 2116%
Cash, Cash Equivalents, and Short-term Investments $118,300,000 USD -36%
Assets, Current $78,183,000 USD -36%
Operating Lease, Right-of-Use Asset $1,516,000 USD
Other Assets, Noncurrent $976,000 USD
Assets $81,175,000 USD -34%
Accounts Payable, Current $494,000 USD 869%
Accrued Liabilities, Current $4,992,000 USD -51%
Liabilities, Current $6,065,000 USD 330%
Operating Lease, Liability, Noncurrent $1,169,000 USD
Liabilities $39,310,000 USD 2684%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,000 USD
Retained Earnings (Accumulated Deficit) $150,001,000 USD 78%
Stockholders' Equity Attributable to Parent $41,865,000 USD
Liabilities and Equity $81,175,000 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,441,000 USD -65%
Net Cash Provided by (Used in) Financing Activities $107,267,000 USD 1530%
Net Cash Provided by (Used in) Investing Activities $40,000,000 USD -4.1%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 18,702,418 shares -84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $99,826,000 USD 4751%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42,887,000 USD 2142%
Deferred Tax Assets, Valuation Allowance $156,546,000 USD -13%
Deferred Tax Assets, Gross $158,410,000 USD -13%
Operating Lease, Liability $1,545,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $11,888,000 USD 69%
Lessee, Operating Lease, Liability, to be Paid $2,227,000 USD
Operating Lease, Liability, Current $376,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $342,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $335,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $682,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $349,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $100,464,000 USD 86%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $356,000 USD
Operating Lease, Payments $0 USD -100%
Additional Paid in Capital $191,858,000 USD -77%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,864,000 USD 273%
Share-based Payment Arrangement, Expense $27,335,000 USD 158%
Interest Expense $1,443,000 USD 1750%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%